1,6-dimethyl-3,4a,5,7,8,8a-hexahydro-2H-pyrido[3,4-b][1,4]oxazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1,6-dimethyl-3,4a,5,7,8,8a-hexahydro-2H-pyrido[3,4-b][1,4]oxazine
• 化学式: C₉H₁₈N₂O
• 分子量: 170.25
• InChiKey: IRNVRTIPEZHPOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C
  申请人：Boehringer Ingelheim International GmbH

  公开号：US10238633B2

  公开（公告）日：2019-03-26

  This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

  本发明涉及式 1 的 2-氮杂双环[2.2.1]庚烷-3-羧酸（苄基-氰基-甲基）酰胺 及其作为 Cathepsin C 抑制剂的用途、含有这些物质的药物组合物，以及将这些物质用作治疗和/或预防与二肽基肽酶 I 活性有关的疾病（如呼吸系统疾病）的药物的方法。
• IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2872514B1

  公开（公告）日：2017-08-30
• SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2970283B1

  公开（公告）日：2020-11-11
• US20140275025A1
  申请人：——

  公开号：US20140275025A1

  公开（公告）日：2014-09-18
• METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20170266160A1

  公开（公告）日：2017-09-21

  This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.